Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2008 May;65(5):767-74.
doi: 10.1111/j.1365-2125.2008.03104.x. Epub 2008 Feb 20.

Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers

R Michael Baldwin  1 , Staffan Ohlsson, Rasmus Steen Pedersen, Jessica Mwinyi, Magnus Ingelman-Sundberg, Erik Eliasson, Leif Bertilsson
Affiliations
Randomized Controlled Trial

Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers

R Michael Baldwin et al. Br J Clin Pharmacol. 2008 May.

Abstract

What is already known about this subject: The only existing study of CYP2C19*17-associated alterations in drug pharmacokinetics was retrospective and compared probe drug metabolic ratios. The CYP2C19*17 allele had been associated with a two- and fourfold decrease in omeprazole and S/R-mephenytoin metabolic ratios.

What this study adds: This study characterized the single-dose pharmacokinetics of omeprazole, along with the 5-hydroxy and sulphone metabolites, in CYP2C19*17/*17 and CYP2C19*1/*1 subjects. The observed differences in omeprazole AUC(infinity) suggest that the CYP2C19*17 allele is an important explanatory factor behind individual cases of therapeutic failure. AIMS To investigate the influence of the CYP2C19*17 allele on the pharmacokinetics of omeprazole, a commonly used CYP2C19 probe drug, in healthy volunteers.

Methods: In a single-dose pharmacokinetic study, 17 healthy White volunteers genotyped as either CYP2C19*17/*17 or CYP2C19*1/*1 received an oral dose of 40 mg of omeprazole. Plasma was sampled for up to 10 h postdose, followed by quantification of omeprazole, 5-hydroxy omeprazole and omeprazole sulphone by high-performance liquid chromatography.

Results: The mean omeprazole AUC(infinity) of 1973 h nmol l(-1) in CYP2C19*17/*17 subjects was 2.1-fold lower [95% confidence interval (CI) 1.1, 3.3] than in CYP2C19*1/*1 subjects (4151 h nmol l(-1), P = 0.04). A similar trend was observed for the sulphone metabolite with the CYP2C19*17/*17 group having a mean AUC(infinity) of 1083 h nmol l(-1), 3.1-fold lower (95% CI 1.2, 5.5) than the CYP2C19*1/*1 group (3343 h nmol l(-1), P = 0.03). A pronounced correlation (r(2) = 0.95, P < 0.0001) was seen in the intraindividual omeprazole AUC(infinity) and omeprazole sulphone AUC(infinity) values.

Conclusions: The pharmacokinetics of omeprazole and omeprazole sulphone differ significantly between homozygous CYP2C19*17 and CYP2C19*1 subjects. For clinically important drugs that are metabolized predominantly by CYP2C19, the CYP2C19*17 allele might be associated with subtherapeutic drug exposure.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) Distribution of area under the concentration–time curve (AUC∞) values for omeprazole, 5-hydroxyomeprazole (5-hydroxy) and omeprazole sulphone (sulphone) in relation to CYP2C19*17/*17 (n = 5) and CYP2C19*1/*1 (n = 11) genotype. (B) Distribution of the ratio of area under the concentration–time curves of omeprazole (OME AUC∞) and 5-hydroxy omeprazole (5-OH AUC∞) in relation to CYP2C19*17/*17 (n = 5) and CYP2C19*1/*1 (n = 11) genotype. Bars represent mean values. Statistical analyses were performed with an unpaired two-tailed heteroscedastic t-test
Figure 2
Figure 2
Correlation of intraindividual omeprazole AUC∞ and metabolite AUC∞ values in CYP2C19*17/*17 (,n = 5) and CYP2C19*1/*1 (•, n = 11) subjects. (A) Relationship between omeprazole AUC∞ and omeprazole sulphone (Sulphone) AUC∞. Linear regression yields r2 = 0.9540 (P < 0.0001). (B) Relationship between omeprazole AUC∞ and 5-hydroxy omeprazole (5-OH) AUC∞. Linear regression yields r2 = 0.5100
See this image and copyright information in PMC

References

    1. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41:913–58. - PubMed
    1. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Sawe J, Villen T. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther. 1989;45:348–55. - PubMed
    1. Qin XP, Xie HG, Wang W, He N, Huang SL, Xu ZH, Ou-Yang DS, Wang YJ, Zhou HH. Effect of the gene dosage of CYP2C19 on diazepam metabolism in Chinese subjects. Clin Pharmacol Ther. 1999;66:642–6. - PubMed
    1. Herrlin K, Yasui-Furukori N, Tybring G, Widen J, Gustafsson LL, Bertilsson L. Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. Br J Clin Pharmacol. 2003;56:415–21. - PMC - PubMed
    1. Sindrup SH, Brosen K, Hansen MG, Aaes-Jorgensen T, Overo KF, Gram LF. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit. 1993;15:11–7. - PubMed

Publication types